A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).

Monica K MalhotraShalu PahujaBrian F KieselLeonard J ApplemanFei DingYan LinHussein A TawbiRonald G StollerJames J LeeChandra P BelaniAlice P ChenVincent L GirandaStacie Peacock ShepherdLeisha A EmensS Percy IvyEdward ChuJan H BeumerShannon Puhalla

Published in: Breast cancer research and treatment (2023)

Veliparib can be safely combined with weekly paclitaxel and carboplatin, and this triplet combination has promising clinical activity.

Keyphrases

phase ii study
open label
phase iii
clinical trial
randomized controlled trial
double blind
energy transfer
study protocol